Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
AMI to become part of Enpro’s Sealing Technologies Segment
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
Sirius JV will be owned 51% by Sirius and 49% by Adani
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
Marks remarkable acceleration in innovation using AI technology
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Karkinos Healthcare has demonstrated exceptional dedication to privacy, setting a commendable example for businesses navigating the complexities of the digital landscape
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
Subscribe To Our Newsletter & Stay Updated
